News
MGNX
5.77
+2.67%
0.15
This Top Insider Is Bulking up on MacroGenics (NASDAQ:MGNX) Stock
TipRanks · 01/24 12:15
Healthcare Outlook 2023
Seeking Alpha · 01/23 15:02
The Latest Analyst Ratings for Macrogenics
Benzinga · 01/19 13:00
Tesla To Rally Around 138%? Here Are 10 Other Analyst Forecasts For Thursday
Benzinga · 01/19 12:57
JMP Securities Maintains Market Outperform on Macrogenics, Lowers Price Target to $8
Benzinga · 01/19 12:23
MacroGenics: Uncertain Revenue Casts A Pall
Seeking Alpha · 01/16 12:32
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
Seeking Alpha · 01/09 14:55
BRIEF-Macrogenics Announces Appointment Of Margaret Liu And Meenu Chhabra Karson To Board
Reuters · 01/04 21:36
Provention Bio: Tzield Finally Approved, But Neutral On Its Commercial Launch
Seeking Alpha · 01/02 17:44
MacroGenics, Inc. (NASDAQ:MGNX) insider upped their holding by 26% earlier this year
Viewing insider transactions for MacroGenics, Inc.'s ( NASDAQ:MGNX ) over the last year, we see that insiders were net...
Simply Wall St. · 12/06/2022 13:01
Can MacroGenics (MGNX) Climb 74% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 73.9% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might transl...
Zacks · 12/05/2022 14:55
MacroGenics (MGNX) Recently Broke Out Above the 20-Day Moving Average
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Zacks · 12/02/2022 14:35
Here's How to Find Cheap Stocks Under $10 to Buy for December
Use one of our Zacks screens to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying heading into December and beyond...
Zacks · 11/29/2022 17:57
7 Analysts Have This to Say About Macrogenics
Benzinga · 11/23/2022 19:01
Expert Ratings for Macrogenics
Benzinga · 11/23/2022 17:02
Baidu To $180? Plus This Analyst Cuts PT On MacroGenics By 56%
Benzinga · 11/23/2022 15:56
Burlington Stores To Surge Over 21%? Plus Wedbush Slashes PT On Jack In The Box
Benzinga · 11/23/2022 13:58
What 7 Analyst Ratings Have To Say About Macrogenics
Benzinga · 11/23/2022 13:02
Where Macrogenics Stands With Analysts
Benzinga · 11/23/2022 12:03
Citigroup Downgrades Macrogenics to Neutral, Lowers Price Target to $7
Benzinga · 11/23/2022 11:25
More
Webull provides a variety of real-time MGNX stock news. You can receive the latest news about Macrogenics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MGNX
MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. It is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.